Silexion Adjourns Shareholder Meeting to Vote on Massive Dilution, Reverse Split, and Equity Plan
SLXN sits 43% above its 52-week low of $0.473 on elevated volume (6.6× avg).
Summary
Silexion Therapeutics has adjourned its Extraordinary General Meeting to May 5, 2026, where shareholders will vote on proposals to significantly increase authorized shares, implement a reverse stock split, and expand its equity incentive plan, all critical for Nasdaq compliance and operational funding amidst a going concern warning.
Key Events · Financing and Capital Events · SLXN
-
Shareholder Meeting Adjourned
The Extraordinary General Meeting, originally scheduled for April 28, 2026, has been adjourned to May 5, 2026, to allow for voting on critical proposals.
-
Massive Authorized Share Increase Proposed
Shareholders will vote on increasing authorized shares by 50,000,000, from 9,000,000 to 59,000,000, to enable future equity raises for Nasdaq compliance and operational funding.
-
Reverse Stock Split Authorization Sought
The Board seeks authorization for a reverse stock split between 1-for-4 and 1-for-10 to maintain the Nasdaq minimum bid price requirement.
-
Equity Incentive Plan Expansion
A proposal to increase the annual "evergreen" provision for the 2024 Equity Incentive Plan to 10% of fully diluted outstanding shares is also on the agenda.
Analysis · SLXN · Life Sciences
This DEFA14A provides an update on the critical shareholder meeting for Silexion Therapeutics, which has been adjourned to May 5, 2026. The company is seeking approval for three highly impactful proposals: a massive increase in authorized shares from 9 million to 59 million, a reverse stock split (1-for-4 to 1-for-10), and an expansion of its equity incentive plan. These measures are explicitly stated as necessary to maintain compliance with Nasdaq listing rules (minimum shareholders' equity and minimum bid price) and to secure "basic financing needs of its operations." Given the company's prior disclosure of a "going concern" warning, these proposals signal a desperate need for capital and a significant potential for dilution for existing shareholders. The outcome of this vote is crucial for the company's ability to continue operations and remain listed.
At the time of this filing, SLXN was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.47 to $22.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.